Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Syngene International Ltd. ( (IN:SYNGENE) ) has shared an announcement.
Syngene International Ltd. has confirmed its expansion of biologics facilities to include new antibody-drug conjugate (ADC) bioconjugation capabilities, as reported in a news article. This strategic move aims to enhance their service offerings by providing end-to-end solutions for ADCs, from discovery to GMP manufacturing, thus accelerating development timelines. While this investment is part of the company’s ordinary business operations, it is not considered ‘material’ under current industry standards.
More about Syngene International Ltd.
Syngene International Ltd. operates in the biotechnology industry, offering integrated research, development, and manufacturing services. The company focuses on providing solutions for pharmaceutical, biotechnology, and agrochemical sectors, with a particular emphasis on biologics and bioconjugation capabilities.
Average Trading Volume: 40,591
Technical Sentiment Signal: Sell
Current Market Cap: 258.6B INR
See more insights into SYNGENE stock on TipRanks’ Stock Analysis page.